Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated adverse events in the digestive system

Li, Yue; Kang, Xiaohui; Wang, Hanping; Guo, Xiaoxiao; Zhou, Jiaxin; Duan, Lian; Si, Xiaoyan; Zhang, Li; Liu, Xiaowei; Qian, Jiaming

doi:10.1111/1759-7714.13338

Cited by 7 publications

(7 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[7][8] However, immunotherapies still have limitations in clinical application such as pseudoprogression, hyperprogression, primary or adaptive drug resistance, and side effects. [9][10][11][12][13] Therefore, it is important to find new immunotherapy targets to improve the efficacy of immunotherapy.…”

Section: Introductionmentioning

confidence: 99%

Fibrinogen like protein-1 knockdown suppresses the proliferation and metastasis of TU-686 cells and sensitizes laryngeal cancer to LAG-3 blockade

Huang

Xue

et al. 2022

J Int Med Res

View full text Add to dashboard Cite

Objective To detect the expression of fibrinogen like protein-1 (FGL-1) in laryngeal cancer and evaluate its effect on tumor proliferation, metastasis, and antitumor immunity. Methods ELISA and immunohistochemistry were performed to detect FGL-1 expression in laryngeal cancer. The effects of FGL-1 knockdown on the proliferation, cell cycle progression, apoptosis, migration, and invasion of laryngeal cancer cells were evaluated by the CCK-8, colony formation, flow cytometry, Transwell migration, and western blot assays. We detected changes in tumorigenesis and drug response in vivo following FGL-1 knockdown as well as the effects of anti-LAG3 immunotherapy. Immunohistochemistry was performed to determine CD8 and LAG-3 expression in mouse tumor tissues. Results FGL-1 was highly expressed in the plasma and tumor tissues of laryngeal cancer patients. FGL-1 knockdown suppressed the proliferation of TU-686 cells and inhibited the migration and invasion of laryngeal cancer by blocking epithelial-to-mesenchymal transition. Moreover, silencing FGL-1 inhibited tumorigenicity in vivo and synergized with anti-LAG3 immunotherapy. Conclusions We confirmed the high expression of FGL-1 in laryngeal cancer and identified FGL-1 as a potential marker for immunotherapy in laryngeal cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Fibrinogen like protein-1 knockdown suppresses the proliferation and metastasis of TU-686 cells and sensitizes laryngeal cancer to LAG-3 blockade

Huang

Xue

et al. 2022

J Int Med Res

View full text Add to dashboard Cite

show abstract

“…The primary symptoms of immune checkpoint inhibitor-induced colitis (ICIIC) include watery stool and non-bloody diarrhea, with abdominal pain, blood in the stool, nausea, vomiting, weight loss, and fever ( 1 ). Studies indicate that patients in the αCTLA-4 group have a higher incidence of GI-irAEs and more frequent diarrhea than patients in the αPD-1/PD-L1 group.…”

Section: Status Quo Of Iciicmentioning

confidence: 99%

“…In recent years, the global cancer incidence has been steadily rising. Traditional cancer treatments include surgery, radiotherapy, chemotherapy, targeted therapy, and interventional therapy ( 1 ). Immunotherapy has become the fifth pillar of cancer management alongside surgery, chemotherapy, radiotherapy, and targeted therapy ( 2 ).…”

Section: Introductionmentioning

confidence: 99%

“…Traditional Chinese medicine (TCM), with a 2,000-year history, complements conventional cancer treatments effectively. TCM combined with antitumor therapy suppresses tumors, reduces drug resistance, and improves patient quality of life ( 1 ). Chinese herbal medicine is affordable, accessible, and minimally disruptive, making it widely accepted by patients.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Potential application mechanism of traditional Chinese medicine in treating immune checkpoint inhibitor-induced colitis

Wang,

Guo,

Shen

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Cancer ranks among the foremost causes of mortality worldwide, posing a significant threat to human lives. The advent of tumor immunotherapy has substantially transformed the therapeutic landscape for numerous advanced malignancies, notably non-small cell lung cancer and melanoma. However, as immune checkpoint inhibitors (ICIs) are increasingly applied in clinical settings, a spectrum of undesired reactions, termed immune-related adverse events (irAEs), has emerged. These adverse reactions are associated with immunotherapy and can result in varying degrees of harm to the human body. Among these reactions, Immune checkpoint inhibitor-induced colitis (ICIIC) stands out as one of the most prevalent clinical adverse events. In contemporary times, traditional Chinese medicine (TCM) has demonstrated remarkable efficacy in addressing various maladies. Consequently, investigating the potential application and mechanisms of Chinese medicine in countering immune checkpoint inhibitor-induced colitis assumes significant importance in the treatment of this condition.

show abstract

“…Additionally, previous studies reported that 9% of 131 evaluable patients were considered to have HP (defined as a twofold increase in the tumor growth rate between the reference and experimental periods) [17]. In addition, patients treated with nivolumab (a humanized mAb against PD-1) were found to be at a higher risk of developing side effects, such as interstitial pneumonia and colitis [21][22][23][24][25]. Most importantly, it has been confirmed that only 20% of patients benefit from immune checkpoint blockade therapy in clinical studies [26], with the rest of the patients showing primary or adaptive drug resistance to varying degrees [27][28][29][30][31][32][33][34][35][36][37].…”

Section: Introductionmentioning

confidence: 99%

Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target

Zhao

Wang

et al. 2021

J Hematol Oncol

View full text Add to dashboard Cite

Immune checkpoint therapy has achieved significant efficacy by blocking inhibitory pathways to release the function of T lymphocytes. In the clinic, anti-programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) monoclonal antibodies (mAbs) have progressed to first-line monotherapies in certain tumor types. However, the efficacy of anti-PD-1/PD-L1 mAbs is still limited due to toxic side effects and de novo or adaptive resistance. Moreover, other immune checkpoint target and biomarkers for therapeutic response prediction are still lacking; as a biomarker, the PD-L1 (CD274, B7-H1) expression level is not as accurate as required. Hence, it is necessary to seek more representative predictive molecules and potential target molecules for immune checkpoint therapy. Fibrinogen-like protein 1 (FGL1) is a proliferation- and metabolism-related protein secreted by the liver. Multiple studies have confirmed that FGL1 is a newly emerging checkpoint ligand of lymphocyte activation gene 3 (LAG3), emphasizing the potential of targeting FGL1/LAG3 as the next generation of immune checkpoint therapy. In this review, we summarize the substantial regulation mechanisms of FGL1 in physiological and pathological conditions, especially tumor epithelial to mesenchymal transition, immune escape and immune checkpoint blockade resistance, to provide insights for targeting FGL1 in cancer treatment.

show abstract

Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated adverse events in the digestive system

Cited by 7 publications

References 22 publications

Fibrinogen like protein-1 knockdown suppresses the proliferation and metastasis of TU-686 cells and sensitizes laryngeal cancer to LAG-3 blockade

Fibrinogen like protein-1 knockdown suppresses the proliferation and metastasis of TU-686 cells and sensitizes laryngeal cancer to LAG-3 blockade

Potential application mechanism of traditional Chinese medicine in treating immune checkpoint inhibitor-induced colitis

Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target

Contact Info

Product

Resources

About